Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Including Oral-Only ESRD Drugs In Payment Bundle Could Harm Access: GAO

Executive Summary

The inclusion of oral-only end-stage renal disease drugs in the Medicare prospective payment system beginning in 2014 could have a negative effect on access to these drugs if facilities consider bundled reimbursement to be inadequate to cover their cost, according to an analysis by the Government Accountability Office.

You may also be interested in...



Bill To Overturn Delay In Bundling Oral-Only Drugs For ESRD Introduced

Rep. Peter Welch introduces a bill that would overturn a provision in the American Taxpayer Relief Act delaying the bundling of oral-only drugs for ESRD treatment, such as Amgen’s Sensipar, until 2016.

Fiscal Cliff Legislation Adjusts ESRD Payment Bundle To Help Offset Doc Fix

In legislation passed by both chambers of Congress Jan. 1, the cost of a one-year reprieve from sharp cuts to Medicare physician payments, scheduled to begin in 2013, would be offset by a reduction in Medicare’s bundled payment for end-stage renal disease. The reduced payment would take into account a drop in the use of erythropoiesis-stimulating agents observed over the last several years.

OIG's 2012 Agenda Includes Several New Part D, Part B Drug Issues

Related Content

Topics

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel